Physician profile
Thomas M Li
NPI 1023005576
$9,115.16
in general payments reported to CMS, 2019-2025
54 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $1,618 · 2021: $1,948 · 2022: $312 · 2023: $962 · 2024: $929 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $895.15 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $780.23 | 2019-2021 | |
| Novo Nordisk INC | $677.98 | 2019-2025 | Wegovy, Saxenda |
| Abbvie INC. | $549.63 | 2019-2025 | |
| Amgen INC. | $382.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $334.18 | 2019-2020 | |
| Exact Sciences Corporation | $332.88 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $290.45 | 2019-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.15 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $225.96 | 2021 | |
| Merck Sharp & Dohme LLC | $222.01 | 2019-2025 | Capvaxive |
| Amneal Pharmaceuticals LLC | $213.14 | 2021-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.82 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $205.78 | 2019-2024 | Veozah |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.